HepCURE × Gilead
Program Briefing
Confidential report
Do not copy or distribute
Confidential report
Confidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distributeConfidential — Do not copy or distribute| Line item | % of funding | Amount |
|---|---|---|
| Sponsorships | ||
| Gilead sponsorship | 20.2% | $130,790 |
| Other sponsorship #1 | 27.8% | $180,000 |
| Other sponsorship #2 | 27.8% | $180,000 |
| CRM sponsorship | 5.6% | $36,000 |
| New mobile unit sponsorship | 9.3% | $60,000 |
| British Columbia expansion sponsorship | 9.3% | $60,000 |
| Total funding received | 100% | $646,790 |
| Costs | ||
| Project Management | −$17,280 | |
| Outreach Events | −$228,000 | |
| Post Outreach — treatment linkage | −$9,685 | |
| Post Outreach — LTFU case management | −$4,680 | |
| Management | −$180,000 | |
| CRM subscription | −$36,000 | |
| New mobile unit — leasing / repairs | −$30,000 | |
| Staff severance | −$30,000 | |
| Total costs | −$535,645 | |
| Net position | +$111,145 | |
Confidential — Do not copy or distribute| Line item | Amount | |
|---|---|---|
| Starting position | ||
| Net position | +$111,145 | |
| Deferred obligations | ||
| CRM sponsorship — repayment owed | −$18,000 | |
| Mobile unit sponsorship — repayment owed | −$30,000 | |
| British Columbia expansion — future obligation | −$60,000 | |
| Adjusted net position | +$3,145 | |
Confidential — Do not copy or distribute| Payment | Date | Amount | Status |
|---|---|---|---|
| Project initiation | January 22, 2026 | $59,450 | Received |
| Project plan | June 11, 2026 | $23,780 | Received |
| Q1 payment | June 11, 2026 | $47,560 | Received |
| Q2 payment | To be issued | $47,560 | Pending |
| Final payment | Due October 31, 2026 | $59,450 | Owed |
| Received to date | $130,790 |
Confidential — Do not copy or distribute| Month | Same day | Few days | Few weeks | Within month | Total |
|---|---|---|---|---|---|
| Oct | — | — | — | — | — |
| Nov | — | — | — | — | — |
| Dec | — | — | — | — | — |
| Q4 Total | — | — | — | — | — |
Confidential — Do not copy or distributeMicro-elimination of HCV among people who use drugs (PWUD) remains constrained by fragmented data, manual case-management workflows, and diagnostic-yield variance. Despite the availability of curative direct-acting antivirals and point-of-care diagnostics, most programs still rely on paper trails, siloed spreadsheets and clinician memory — creating avoidable losses along the cascade of care.
HepCURE deployed a purpose-built CRM engineered mobile-first for tablet and smartphone use — traditional laptops are impractical in mobile outreach. It integrates client registrations, HCV / HIV POCT, Cepheid RNA confirmatory testing, DBS, dispositions and case management into a single longitudinal record. An AI layer classifies each client's cascade position in real time, flags follow-up drift, models optimal outreach geography, and produces reconciled sponsor scorecards. A conversational AI agent answers natural-language questions on any collection point, rendering results as dashboard visuals. Customizable data markers extend the schema on-demand, capturing emergent variables and surfacing live insights to refine the model of care. Two mobile teams operated Jan–Jul 2026 across 29 Ontario communities and 144 outreach days.
2,590 at-risk clients were screened; 415 (16.0%) confirmed RNA-positive, of whom 350 (84.3%) were linked to care. Team-level analytics revealed a 1.9× yield differential (Team 2: 23.5% vs Team 1: 12.6% RNA-positive rate) that directly informed screening-protocol refinement. 3,450 clinical assessments (1.33 per client) were tracked across POCT HCV, POCT HIV, Cepheid and DBS modalities with zero reconciliation errors between team-level and program-wide reporting.
AI-enabled, CRM-driven workflow is the missing operational layer in HCV elimination for PWUD — turning static outreach data into a real-time optimization loop that elevates decision-making, surfaces yield variance, compresses the cascade and eliminates reporting drift. The platform is model-of-care agnostic and directly replicable in other Canadian jurisdictions and internationally. To our knowledge, this is the first HCV / HIV elimination abstract centered on AI and CRM technology.
Confidential — Do not copy or distribute
